TScan Therapeutics TCRX Cash Flow Statement (2020-2026)

NASDAQ TCRX
$0.20 -0.01 (-6.01%)
At close: Oct 23, 2026 · 4:00 PM EDT
Reported Financials

TScan Therapeutics Quarterly Cash Flow Statement

Periods 25 quarters
Latest Jun 2026

TScan Therapeutics reported cash from operations of -$27.54M and free cash flow of -$28.03M for the quarter ended Jun 2026, up 17.2% year over year. This cash flow statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-15.84M-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-35.81M-34.13M-36.95M-35.71M-22.98M-28.67M-30.36M
Depreciation and DepletionDep. & Depletion
1.06M1.14M1.20M1.21M1.25M1.48M1.50M1.30M1.29M1.28M1.25M1.12M1.03M0.71M0.68M0.70M0.77M0.72M0.69M0.70M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
1.06M1.14M1.20M1.21M1.25M1.48M1.50M1.30M1.29M1.28M1.25M1.12M1.03M0.71M0.68M0.70M0.77M0.72M0.69M0.70M
Share-based CompensationStock Comp.
0.89M0.78M0.98M1.02M1.25M1.30M1.15M1.22M1.34M1.50M1.98M2.33M2.52M2.71M3.41M3.27M3.01M2.01M2.47M2.36M
Other non-cash itemsOther Non-Cash
0.22M0.21M0.22M-0.01M-1.49M-0.25M-0.19M-1.30M-1.06M-1.17M-0.67M-0.17M-0.40M0.12M0.13M
Change in Working Capital
Change in Account PayablesChange Payables
0.88M-2.46M0.82M0.41M-1.12M0.41M0.50M0.37M-0.27M-0.64M-0.41M0.40M1.03M0.98M0.56M-0.44M1.93M-5.07M1.05M0.84M
Change in Accured ExpensesChange Accured Exp.
1.71M1.85M-2.80M0.61M1.60M1.32M0.74M0.78M1.02M1.31M-1.60M1.95M0.53M3.66M-5.41M2.67M-1.11M-3.38M0.90M-0.74M
Change in Other Operating AssetsOther Assets Change
0.82M-0.44M2.11M-1.21M1.50M-1.99M1.18M-2.91M0.69M0.05M-0.26M0.02M1.17M-0.39M0.52M-0.04M-0.87M0.90M-0.13M-0.48M
Change in Other Operating LiabilitiesOther Liabilities Change
-1.52M-1.93M-2.07M-2.73M-2.27M-4.01M-3.94M27.16M-3.58M-6.82M-0.35M-0.14M-0.66M0.22M-1.00M-1.89M-2.05M-2.48M-0.97M-1.04M
Other Working Capital ChangesOther WC Changes
-2.33M-1.49M-4.18M-1.52M-3.78M-2.02M-5.12M30.07M-4.28M-6.87M-0.10M-0.16M-1.83M0.61M-1.53M-1.85M-1.18M-3.38M-0.84M-0.56M
Cash from OperationsCash from Ops.
-13.64M-14.38M-20.12M-13.37M-17.00M-16.01M-23.59M-22.02M8.02M-23.77M-29.27M-26.23M-27.92M-27.41M-37.59M-33.27M-32.46M-32.00M-24.28M-27.54M
Investing Activities
Capital ExpendituresCapex
0.85M2.21M0.53M1.89M0.42M1.38M0.84M0.42M1.42M0.47M0.71M0.86M1.37M0.89M1.53M1.28M1.43M0.17M0.07M0.49M
Change in Property, Plant and EquipmentChange in PP&E
-0.85M-2.21M-0.53M-1.89M-0.42M-1.38M-0.84M-0.42M-1.42M-0.47M-0.71M-0.86M-1.37M-0.89M-1.53M-1.28M-1.43M-0.17M-0.07M-0.49M
Purchase of InvestmentsInvestments Purchased
17.62M8.78M48.35M136.98M47.33M60.94M26.53M0.00M
Sale and Maturity of InvestmentsInvestments Sold
45.65M15.50M56.00M75.51M76.00M76.25M34.00M15.00M
Cash from Investing ActivitiesCash from Investing
-0.85M-2.21M-0.53M-1.89M-0.42M-1.38M-0.84M-0.42M-61.41M1.91M36.16M-33.72M-82.35M27.29M13.53M48.44M32.58M14.83M-0.07M-0.47M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
89.65M0.12M0.09M0.03M0.01M0.20M-0.25M0.02M0.26M161.59M1.23M30.38M0.07M
Net Shares Issued and RepurchasedNet Shares Issued
89.65M0.12M0.09M0.03M0.01M0.20M-0.25M0.02M0.26M161.59M1.23M30.38M0.07M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
89.65M0.12M0.09M0.03M0.01M0.20M-0.25M0.02M0.26M161.59M1.23M30.38M0.07M
Other financing activitiesOther financing
0.96M-0.23M-0.09M-0.13M-0.08M
Cash from Financing ActivitiesCash from Financing
90.61M0.12M0.09M0.03M29.13M0.11M-0.25M0.02M0.26M161.59M1.23M45.69M-0.53M0.12M0.07M
Additional items
Change in Cash
76.12M-16.47M-20.57M-15.23M11.70M-17.28M-24.43M113.23M-53.65M-21.83M7.15M101.65M-109.04M45.57M-24.58M15.29M0.11M-17.10M-24.35M-27.90M
Ending Cash Balance
182.91M166.44M145.87M130.64M142.34M125.06M100.64M213.87M160.22M138.39M145.54M247.19M138.15M183.72M159.14M174.43M174.54M157.44M133.09M105.19M
Free Cash FlowFCF
-14.49M-16.59M-20.66M-15.26M-17.43M-17.39M-24.43M-22.44M6.60M-24.24M-29.97M-27.09M-29.29M-28.30M-39.12M-34.55M-33.89M-32.17M-24.35M-28.03M
Net Cash FlowNCF
76.12M-16.47M-20.57M-15.23M11.70M-17.28M-24.43M-22.44M-53.65M-21.83M7.15M101.65M-109.04M45.57M-24.58M15.29M0.11M-17.10M-24.35M-28.00M
Interest Paid
0.74M0.76M0.76M0.74M0.76M0.75M0.76M0.61M0.57M0.58M0.58M0.58M0.57M0.58M

TScan Therapeutics Cash Flow Statement API

Pull TScan Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TCRX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY